Efficacy News and Research

RSS
Researchers develop automated venipuncture device that automates phlebotomy procedure

Researchers develop automated venipuncture device that automates phlebotomy procedure

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

Patient's own bone-marrow stromal cells could treat multi-drug resistant TB

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Neurovance announces interim results from phase 2a pilot study of EB-1020 SR in patients with all subtypes of ADHD

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Altheus Therapeutics completes enrollment for Phase 2 trial of Zoenasa Rectal Gel for distal ulcerative colitis

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Mild electronic stimulation therapy to upper airway during sleep effective in reducing OSA

Mild electronic stimulation therapy to upper airway during sleep effective in reducing OSA

Merck announces FDA approval of ISENTRESS for oral suspension

Merck announces FDA approval of ISENTRESS for oral suspension

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

OASIS receives research award from MJFF to develop saliva-based, rapid test for Parkinson's detection, diagnosis

Sanford Health gifts $125M to establish Imagenetics program that integrates genomic medicine into primary care for adults

Sanford Health gifts $125M to establish Imagenetics program that integrates genomic medicine into primary care for adults

Study: Combined medications may improve smoking cessation than single drug therapy

Study: Combined medications may improve smoking cessation than single drug therapy

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Insight Genetics receives $1.5M SBIR contract to research on resistance mutations in NSCLC patients

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Cornell biomedical engineers identify new way to destroy metastasizing cancer cells

Research opens door to new direction of PAH treatment

Research opens door to new direction of PAH treatment

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

First patient enrolled in the North American Phase 3 clinical trials for investigational flu treatment drug

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.